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Summary Sterculic acid, a A-9-desaturase inhibitor, administered to rats caused a rise in the stearic:oleic acid
ratio of total lipids in peripheral red cells, serum and liver (P <0.001). As a reduction in the stearic:oleic acid
ratio has been described in cancer cells, we investigated the effect of sterculic acid on tumour growth. Female
F344 rats were injected subcutaneously with two different doses of sterculic acid for 4 weeks prior to, and 4
weeks following, implantation of a nitrosomethylurea-induced mammary tumour. Tumour growth was
inhibited equally by the two doses of sterculic acid (P <0.001). A rise in the stearic:oleic acid ratio of tumours
was observed in rats treated for only 16 days with sterculic acid. Manipulation of the tissue stearic:oleic acid
ratio inhibits transplanted mammary tumour growth in rats.
Fats have long been linked to cancer promotion.
Epidemiological studies have shown that dietary factors, and
in particular fat, are linked to several cancers including
breast and colon cancer (Segi et al., 1966; Drasar &
Irving, 1973). Monounsaturated, saturated and polyun-
saturated fats were found to correlate with breast cancer
incidence in a case control study (Miller et al., 1978).
Although such studies do not demonstrate a strong link with
any particular type of fat, experimental models of several
cancers, including colon and breast cancer, have shown that
polyunsaturated fats are more potent promoters of mammary
cancer than saturated fats (Carroll & Khor, 1971; Rao &
Abraham, 1976). The relative tissue content of saturated and
unsaturated fatty acid may be important in tumour promo-
tion. When individual fatty acids were investigated, linoleate
and oleate increased the growth of nitrosomethylurea-
induced mammary tumour in vivo (Chan et al., 1983). By
contrast, stearic acid inhibited mammary tumour cells in vitro
(Doi et al., 1978; Wicha et al., 1979) and also in vivo (Ben-
nett, 1984; Habib et al., 1987). Stearic acid may inhibit
cancer cell growth by increasing the cellular stearic:oleic acid
ratio and hence the balance of saturated and unsaturated
fatty acids in the tissues. The desaturation of stearic to oleic
acid is mediated by A-9-desaturase an important enzyme in
the control of tissue fatty acid desaturation. Inhibition of this
enzyme, therefore, may inhibit cancer cell growth. Sterculic
acid is the most potent A-9-desaturase inhibitor known and
is itself a naturally occurring cyclopropene fatty acid derived
from a number of plant sources such as Sterculia foetida seed
oil. It inhibits the A-9-desaturate system, and de novo syn-
thesis of saturated fatty acids and cholesterol, is unaffected
(Zoeller & Wood, 1985).
The aims of this study were to assess the tolerability of
injected sterculic acid in rats and its effect on tissue fatty acid
composition and to relate tissue fatty acid composition to




Fischer F344 rats were obtained from Harlan Olac Ltd
(Bicester, UK) and were maintained in a 12-hour light/dark
cycle. They were fed a standard diet (CRM; Biosure Ltd,
Cambridge, UK) and water ad libitum. Male rats aged 4-6
weeks were used to investigate the effects of sterculic acid on
body fat composition, and for the other experiments, female
rats aged 4-6 weeks were used.
Sterculic acid
Sterculic acid (98% pure) was obtained from Reading
Scientific Ltd (Reading, England). It was blown with nitro-
gen and stored in sealed containers at - 20°C. It was dis-
solved in liquid paraffin to a volume of 0.5 ml before
administration by subcutaneous injection.
The effect of sterculic acid on body fat acids
The rats were randomised to a treated group which received
sterculic acid (0.125 ml (90 mg) diluted 1:4 with liquid
paraffin) by subcutaneous injection three times a week and
an untreated control group. Blood for fatty acid analysis was
taken from the lateral tail vein under anaesthetic at fort-
nightly intervals. Thirteen animals completed the experiment
in the treated group and 11 animals in the control group
owing to deaths occurring under anaesthetic. Treatment was
continued for 18 weeks and the animals were then anaes-
thetised and killed by exsanguination using cardiac puncture.
The blood samples were centrifuged at 200g to separate the
plasma. The red cells were washed in cold (4°C) sterile
phosphate-buffered saline three times, resuspended to a dilu-
tion of 1:4 in phosphate-buffered saline and stored at - 20°C
until used for fatty acid analysis. Samples were taken from
liver and brain, blown with nitrogen, snap frozen in liquid
nitrogen, and stored at - 70°C. Lipid extractions were per-
formed within 1 week.
The effect of sterculic acid on mammary tumour growth
A mammary tumour was induced with nitrosomethylurea
and passaged in F344 rats. A single tumour was used in its
fourth passage from one animal. Thirty-six rats were ran-
domly assigned to treatment with either sterculic acid
0.125 ml (90 mg), sterculic acid 0.025 ml (18 mg) or control
liquid paraffin by subcutaneous injection in the right flank
for 4 weeks prior to tumour implantation. This period of
injection with sterculic acid prior to implantation was chosen
because significant erythrocyte fatty acid changes were only
observed after 4 weeks in the first investigation (results not
presented). The animals were weighed every week during the
experiment. Each animal was then transplanted with a
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1 mm x 4 mm disc of tumour in the left flank under anaes-
thesia (Hypnorm; Janssen Pharmaceuticals Ltd, UK). Injec-
tions of sterculic acid were continued for 4 weeks, and serial
tumour volumes were estimated at 2, 3 and 4 weeks from
caliper measurements in two planes using the formula: (max.
dimension) x (min. dimension)2 (Attia & Weiss, 1966). When
the first of the animals developed tumours that were 25% of
body weight, all were killed using CO2 anaesthesia. Their
tumours were dissected out and weighed. Measurements were
performed by an assistant who was unaware of the treatment
groups.
The effects of sterculic acid on the fatty acid composition
of this tumour was investigated in a separate investigation.
Tumour fragments were implanted subcutaneously in 16 rats
which were then allocate to receive either sterculic acid
0.125 ml in 0.5 ml liquid paraffin (n = 8) or liquid paraffin
0.5 ml (n = 8). After 16 days the animals were killed and
their tumours and livers were subject to fatty acid analysis as
described above.
Lipid extraction
At all times the samples were kept under nitrogen gas. All
solvents used in the extraction procedure were redistilled and
blown with nitrogen. Lipids from the liver and brain were
extracted by the Folch method (Folch et al., 1957). One
hundred micrograms of tissue was homogenised in 0.5 ml
methanol, and then vortexed in 1.4 ml methanol in
chloroform (2:19). It was then revortexed with a further
0.4 ml methanol and centrifuged at 4°C for 10 min at 600 g
to remove protein debris. Chloroform (0.7 ml) was added to
2 ml of the supernatant followed by distilled water (0.6 ml).
The lower phase was washed three times with 1 ml pure
solvent upper phase (CHC13: MeOH:distilled water; 3:48:47)
and 0.2 ml methanol was added. Lipids were extracted from
the red cells after the method of Slayback et al. (1977). A
dilute red cell suspension (100 gil) was added to 0.9 ml
phosphate-buffered saline and I ml acetone and incubated at
90°C for 2 min. The mixture was vortexed with 2 ml of
ethylacetate and incubated at 65°C for 20 min, revortexed
and incubated for a further 20 min at 65°C. After centrifuga-
tion at 200 g for 10 min, the aqueous phase was removed.
Fatty acid extraction
The lipid extract was dried down under nitrogen and free
fatty acids were liberated by saponification with I ml 15%
methanolic KOH followed by incubation at 65°C for 30 min.
This mixture was diluted with I ml distilled water and
acidified with 0.6 ml 4N HCI. Free fatty acids were liberated
by adding 2 ml benzene. After centrifugation at 200 g, the
bottom phase was discarded. The fatty acids were methylated
by the addition of I ml 15% boron trichloride in methanol
and then incubation at 95°C for 10 min. After cooling, 2 ml
distilled water added to remove unwanted salts and boron
trichloride. After centrifugation, the top layer was removed,
dried down in an autoloader capsule and redissolved in 3-8
drops of trimethylpentane and sealed under nitrogen.
Gas-liquid chromatography analysis
The fatty acid methyl esters (FAME) were analysed by
temperature-programmed (160-260°C at 4°C per minute)
gas-liquid chromatography (GLC), using a Phillips PU4550
gas chromatograph, with a 2.1 mm x 2 m i.d. glass column
packed with 3% SP-2310/2% SP-2300 on 100/200 mesh
Chromosorb W (Supelco Inc). The carrier gas was nitrogen
at a flow rate of 20 ml min- . Detection was by flame ionisa-
tion, and individual FAMEs were identified by comparison
of retention times with three authenticated FAME standards
(Sigma Chemicals Co. Ltd). A sample control was also run.
The relative concentrations of fatty acids were determined
from the areas under the peaks.
Statistical analysis
One-way analysis of variance (ANOVA) with contrasts for
multiple comparisons was used for the tumour weights. Each
tumour growth curve was cube-root transformed and the
resulting linear slopes were compared using ANOVA with
contrasts. Unpaired t-tests were used to compare the individ-
ual fatty acids in the different groups.
Results
No macroscopic evidence of toxicity was observed in the
sterculic acid treated animals and there was no evidence of
weight loss or debility in the tumour bearing animals treated
with sterculic acid compared with controls. In all tissues
other than brain in which total lipids were analysed, there
was a rise in stearic:oleic acid ratio (P <0.001) brought
about by a fall in C1 8: 1 (oleic acid) and (except in the
erythrocytes) a rise in C18:0 (stearic acid). Also, there was a
rise in C18:2 (linoleic acid) and a fall in C20:3/4
(eicosatrienoic/arachidonic acid). There was no change in the
linolenic acid fraction (C18:3) (Table I).
Tumour growth was inhibited in the sterculic acid treated
animals as compared with controls (P <0.001 for both
doses; Figure 1). The final tumour weight of the treated
animals were almost one-half of the tumour weights of the
control animals 4 weeks after implantation (P <0.01 for
both doses; Table II).
Small differences in the weights of the animals were found
between the different groups but their overall growth rate did
not differ (Figure 2). After tumour implantation, the rate of
weight gain in the control animals exceeded that of the
treated ones. This is accounted for by the larger tumours in
the control animals.
After 16 days, tumours of animals treated with sterculic
acid demonstrated a significant rise in stearic acid content
(P <0.01), a fall in oleic acid content (P <0.05) giving rise
to a higher ratio of stearic to oleic acid (P <0.002; Table
III). The final tumour weights were slightly lower in the
sterculic acid group (19.7 ± 3.4 g) compared with controls
(32.5 ± 5.9 g) (P < 0.05).
Discussion
Sterculic acid, by subcutaneous injection in non-tumour-
bearing animals, had major effects on body fat composition.
The main changes were seen in liver, plasma and erythrocyte
stearic and oleic acid fractions resulting in a rise in the
stearic:oleic acid ratio; this effect is expected from inhibition
of A-9-desaturase by sterculic acid. In addition, there was a











0 1 2 3 4
Weeks after tumour implantation
Figure 1 The effect of sterculic acid on the growth of a
nitrosomethylurea-induced transplanted mammary tumour in rats
(P <0.001; two-way analysis of variance). 0- Control;
-O Sterculic Acid 90 mg; A- Sterculic Acid 18 mg.
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arachidonic/eicosatrienoic acid fraction which can be
explained by inhibition of A-6-desaturase activity. This sug-
gests that sterculic acid is not only an inhibitor of A-9-
desaturase as has been previously reported in vitro (Jeffcoat
& Pollard, 1977). A rise in linoleic acid and a fall in C20:3/4
fatty acids was also noted in a previous report on the effects
of dietary sterculate in rats (Pullarkat et al., 1976). In this
same report, brain lipids were not affected to the same extent
as liver lipids, and sterculate was not found in the brain
suggesting it does not cross the blood-brain barrier. Sterculic
acid was capable of causing the same changes in tumour
_0 o ~ o o o i; o ofatty acids (Table III). It is likely, therefore that lipid changes
u 0 665 o6 6o in tumour may have been responsible for the inhibition of
o +1+ +1 +1 +1 +1 +1 +1 tumour growth observed.
NON> OONo X , 00 a'sThere was complete tumour take in the second experiment,
0
o indicating that the process of implantation was not inhibited
by the fatty acid changes in the host induced by prior6 6o treatment with sterculic acid. However, tumour growth was
+1+1 inhibited by almost 50% by sterculic acid and it is likely that
0 >0~ this effect is related to the fatty acid changes in the animals
and tumours. When sterculic acid was administered followingo
e " 1- 0.0o tumour implantation, the fatty acids of the tumour are0 0 6 6 66 6 6 indeed changed in exactly the same pattern as was observed
+1 +1 +1 +1 +1 +1 +1 +1X O co00X in the first experiment (Table II) and tumour growth was
6 6C> i 6 6 6 inhibited although to a lesser extent. The stearic:oleic acid
e a-, - £fO ratio was found to be reduced in a number of tumour cell
0 0 6 6 6 6 6 6o lines, such as hepatoma (Ruggieri & Fallani, 1979) ando o +1+1 +1 +1 +1 +1 +1 +1 melanoma (Calorini et al., 1987), and was also lower inX 00 0 human liver neoplasms compared with normal liver (Wood et3 6 'O- 6 -> 0 0o al., 1985). Malignant cells from patients with leukaemia were
found to have a lower stearic:oleic acid ratio when compared^ 66 66 o oowith normal white cells (Apostolov et al., 1985). Increased
+1 +1+1 +1+1 A-9-desaturase activity, therefore, may be a feature of the
E4 ~ oomalignant phenotype. It may be that the increase in
C> 6 6 stearic:oleic acid ratio in tumours in response to sterculic
t 3 oDo t- > xo acid selectively affects growth because tumours have a lowerX o N o - 6 6o 6 6 stearic:oleic acid ratio than normal tissue.
00 +1 +1 +1 +1 +1 +1 +1 +1
ou"Cc _ The lack of dose dependence in this study is surprising; it






_over this particular dose range. It is interesting to compareoi t to N ^ > t eo xthis result with that of Karmali et al. (1984) who showed that
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Treatment Tumour weight (g)
Control 47.1 (± 6.2)
Sterculic acid 90 mg 23.3 (± 4.0)a
Sterculic acid 18 mg 27.2 (± 3.3)a
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Figure 2 The effect of sterculic acid on the growth rate (percent-
age change from initial weight) of rats (n.s.; two-way analysis of
variance). -0- Control; -0- Sterculic Acid 90mg; A








100 D.E. KHOO et al.
Table III The effect 0.125 ml sterculic acid SC on alternate days on the fatty acid composition of total lipid extracts
from a mammary tumour
Tumour Percentage fatty acids (mean ± standard error)
tissue 16:0 18:0 18:1 18:2 20:0 20:1 22:0 18:0/18:1
Control 32.55 ± 0.86 27.53 ± 0.73 35.91 ± 1.10 3.29 ± 1.12 0.46 ± 0.09 0.07 ± 0.03 0.20 ± 0.06 0.77 ± 0.03
Treated 31.07 ± 0.87 31.15 ± 0.95b 32.34 ± 1.24a 3.38 ± 1.63 0.24 ± 0.07 0.89 ± 0.78 0.51 ± 0.26 0.98 ± 0.05c
Comparison of sterculic group with controls atfer 16 days. ap <0.05; bp <0.01; CP <0.002.
mammary tumour equally over a four-fold dose range.
The experimental evidence from animal work supports the
hypothesis that fat is a tumour promoter. Unsaturated fat
diets produced a greater yield of 7,12-dimethyl-
benzanthracene-induced mammary tumours in rats than
saturated fats, and when a minimal requirement for
unsaturated fats was satisfied, the type of fat required for
promotion was immaterial (Carroll & Hopkins, 1979). How-
ever, a diet containing saturated fat with a minimal
unsaturated fat content did not promote tumour yield more
than a low-fat diet (Braden & Carroll, 1986). The effects of
individual fatty acids have not been investigated as fully as
those of lipids, but several studies now support the
hypothesis that some fatty acids may actually inhibit cancer.
When compared with a control diet, a diet containing 14%
stearic acid reduced the yield and prolonged the latency of
spontaneously developing mammary carcinomas in strain A/
St mice (Bennett, 1984). Both injected stearic acid and an
iodinated analogue, iodostearic acid, were also shown to
inhibit nitrosomethylurea-induced mammary carcinogenesis
in rats, and using in vitro clonogenic assay malignant cells
were selectively inhibited (Habib et al., 1987). Stearic acid
inhibited the growth of mouse LM cells in vitro (Doi et al.,
1978), and the growth of neoplastic rat mammary epithelial
cells was inhibited by stearic acid whereas monounsaturated
fatty acids such as oleic acid and polyunsaturated fatty acids
promoted growth in vitro (Wicha et al., 1979). When several
endogenous faecal diglycerides were tested for mitogenic
potential in colonic adenoma cells in vitro, it was found, with
one exception, that all diglycerides stimulated mitogenesis; if
the diglyceride contained even a single stearic acid residue,
mitogenesis was completely inhibited (Friedman et al., 1989).
If the stearic:oleic acid ratio were increased by inhibition
of A-9-desaturase, tumour growth inhibition would possibly
be expected. Sterculic acid, as a potent specific inhibitor of
the A-9-desaturase enzyme (Jeffcoat & James, 1984), is
known to increase the stearic:oleic ratio when fed to rats
(Reiser & Raju, 1964; Matlock et al., 1985). Other agents
with antineoplastic activity such as retinoids and interferon
appear to inhibit A-9-desaturase activity (Alam et al., 1984;
Apostolov & Barker, 1981). Contrary to our findings, how-
ever, sterculic acid was found to be a promoter of 2'-
acetoaminofluorene-induced liver carcinogenesis in trout (Lee
et al., 1968). Moreover when applied to hepatoma cells in
vitro, no inhibition of doubling time was observed (Zoeller &
Wood, 1985). This contrasts with our own findings in which
malignant cell growth was inhibited in vitro by sterculic acid
(unpublished data).
There are several possible mechanisms by which an in-
crease in the stearic:oleic acid ratio inhibits malignant cell
growth. A reduction in the overall cell membrane fatty acid
desaturation may reduce membrane fluidity (Boonstra et al.,
1982) and small changes in membrane fluidity may cause
profound changes in cell membrane receptor function or
antigen expression (Sandermann, 1978). Aylsworth et al.
(1987) showed that oleic acid inhibited gap junction intercel-
lular communication whereas saturated fatty acids, including
stearic acid, had the opposite effect and suggest that this is
the mechanism whereby fats promote tumour growth. Inhibi-
tion of protein kinase C activity is suggested as the reason
for the effects of fatty acid on gap junctions.
In summary, the result of this investigation supports the
hypothesis that a change in C18 fatty acid saturation is
important in cancer promotion. This study has shown for the
first time that sterculic acid may inhibit tumour growth. The
mechanism by which this A-9-desaturase inhibitor has an
antineoplastic action is yet to be elucidated. Further studies
of sterculic acid and other A-9-desaturase inhibitors are plan-
ned.
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